ArticleTherapeutic advances in drug safety2013
Safety of antiobesity drugs.
Article in Therapeutic advances in drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04481464 (Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity), which is not on this map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity: a Retrospective Study
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis.Journal of general internal medicine · 2026Pooled it
- Pooled it
- Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016Pooled it
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.BMC medicine · 2016Pooled it
- A Randomized Clinical Trial of a Tailored Lifestyle Intervention for Obese, Sedentary, Primary Care Patients.Annals of family medicine · 2016Trial
- Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study.Journal of obesity · 2015Trial
- Evaluation of 3',4'-Di-Biomolecules · 2026Article
- The effect of beinaglutide on visceral fat and body weight in obese type 2 diabetic patients.Archives of medical science : AMS · 2026Article
- Major phenolic compounds in Korean red pine (Food science and biotechnology · 2026Review
- Therapeutic Potential of Santa Herba Extract in Obesity: Impact on Lipid Metabolism and Hormonal Balance.Food science & nutrition · 2025Article
- Impact on Metabolism Generated by Surgical and Pharmacological Interventions for Weight Loss in Women with Infertility.Metabolites · 2025Review
- Methodological insights into intervention and outcomes in randomised controlled trials of herbal medicine for obesity: a scoping review.Therapeutic advances in chronic disease · 2025Article
- White Tea Consumption Alleviates Anthropometric and Metabolic Parameters in Obese Patients.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- Association of semaglutide with risk of suicidal ideation in a real-world cohort.Nature medicine · 2024Article
- Betanin from Beetroot (Pharmaceuticals (Basel, Switzerland) · 2023Article
- Advances in oligosaccharides production from brown seaweeds: extraction, characterization, antimetabolic syndrome, and other potential applications.Bioengineered · 2023Review
- Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA.Nature metabolism · 2023Article
- The Effect of Nanobubble Water Containing Cordyceps Extract and Withaferin A on Free Fatty Acid-Induced Lipid Accumulation in HepG2 Cells.Nanomaterials (Basel, Switzerland) · 2023Article
- Inhibition of lipid droplet accumulation byExperimental and therapeutic medicine · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major health problem worldwide. Although diet and physical activity are crucial in the management of obesity, the long-term success rate is low. Therefore antiobesity drugs are of great interest, especially when lifestyle modification has failed. As obesity is not an immediate life-threatening disease, these drugs are required to be safe. Antiobesity drugs that have been developed so far have limited efficacies and considerable adverse effects affecting tolerability and safety. Therefore, most antiobesity drugs have been withdrawn. Fenfluramine and dexfenfluramine were withdrawn because of the potential damage to heart valves. Sibutramine was associated with an increase in major adverse cardiovascular events in the Sibutramine Cardiovascular Outcomes (SCOUT) trial and it was withdrawn from the market in 2010. Rimonabant was withdrawn because of significant psychiatric adverse effects. Orlistat was approved in Europe and the United States for long-term treatment of obesity, but many patients cannot tolerate its gastrointestinal side effects. Phentermine and diethylpropion can only be used for less than 12 weeks because the long-term safety of these drugs is unknown. Ephedrine and caffeine are natural substances but the effects on weight reduction are modest. As a result there is a huge unmet need for effective and safe antiobesity drugs. Recently lorcaserin and topiramate plus phentermine have been approved for the treatment of obesity but long-term safety data are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.